Related Experiment Video
Updated: Jan 3, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass
Douglas Nogueira Perez Oliveira1, Anting Liu Carlsen2,3, Niels H H Heegaard2
1Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Background:
Ovarian cancer is the fifth most common cancer in women worldwide. Moreover, there are no reliable minimal invasive tests to secure the diagnosis of malignant pelvic masses. Cell-free, circulating microRNAs have the potential as diagnostic biomarkers in cancer. Here, we performed and validated a miRNA panel with the potential to distinguish OC from benign pelvic masses.
Methods:
The profile of plasma microRNA was determined with a panel of 46 candidates in a discovery group and a validation group, each consisting of 190 pre-surgery plasma samples from age-matched patients with malignant (n = 95) and benign pelvic mass (n = 95), by real time RT-qPCR.
Results:
Four up-regulated (miR-200c-3p, miR-221-3p, miR-21-5p, and miR-484) and two down-regulated (miR-195-5p and miR-451a) microRNAs were discovered. From those, miR-200c-3p and miR-221-3p were further confirmed in a validation cohort. A combination of these 2 microRNAs together with CA-125 yielded an overall diagnostic accuracy of AUC = 0.96.
Conclusions:
We showed consistent plasma microRNA profiles that provide independent diagnostic information of late stage OC.
